Outcomes of Impella 5.0 and 5.5 for cardiogenic shock: A single‐center 137 patient experience

Background This study evaluated the outcomes of patients with cardiogenic shock (CS) supported with Impella 5.0 or 5.5 and identified risk factors for in‐hospital mortality. Methods Adults with CS who were supported with Impella 5.0 or 5.5 at a single institution were included. Patients were stratified into three groups according to their CS etiology: (1) acute myocardial infarction (AMI), (2) acute decompensated heart failure (ADHF), and (3) postcardiotomy (PC). The primary outcome was survival, and secondary outcomes included adverse events during Impella support and length of stay. Multivariable logistic regression was performed to identify risk factors for in‐hospital mortality. Results One hundred and thirty‐seven patients with CS secondary to AMI (n = 47), ADHF (n = 86), and PC (n = 4) were included. The ADHF group had the highest survival rates at all time points. Acute kidney injury (AKI) was the most common complication during Impella support in all 3 groups. Increased rates of AKI and de novo renal replacement therapy were observed in the PC group, and the AMI group experienced a higher incidence of bleeding requiring transfusion. Multivariable analysis demonstrated diabetes mellitus, elevated pre‐insertion serum lactate, and elevated pre‐insertion serum creatinine were independent predictors of in‐hospital mortality, but the etiology of CS did not impact mortality. Conclusions This study demonstrates that Impella 5.0 and 5.5 provide effective mechanical support for patients with CS with favorable outcomes, with nearly two‐thirds of patients alive at 180 days. Diabetes, elevated pre‐insertion serum lactate, and elevated pre‐insertion serum creatinine are strong risk factors for in‐hospital mortality.